Enlivex Ltd.
ENLVHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeEnlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Valued at $79.6M, ENLV is a micro-cap name in its sector. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Market Cap
$79.6M
Beta
1.52
P/E (TTM)
0.01
P/E (Fwd)
-6.06
EPS (TTM)
$388.99
EPS (Fwd)
$-0.78
ROE
126.2%
ROA
-0.8%
Cash
$5.8M
Total Debt
$641,000
Free CF
-$1.74B
52W Change
-73.3%
Annual Financials
Cash vs Debt
Where ENLV stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ENLV finished 54.24% below its 150-day moving average ($13.22) and 56.22% below its 200-day moving average ($13.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ENLV overbought or oversold?
At the July 15, 2026 close, ENLV's RSI(14) was 8.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $5.8M in cash comfortably exceeding the $641K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$1.74B, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 126.2% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.52 means ENLV is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, ENLV has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ENLV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.